Clinical Study on Heavy Ion Therapy for High-Grade Glioma Continues

Clinical Study on Heavy Ion Therapy for High-Grade Glioma Continues

The Lanzhou Heavy Ion Center of Gansu Wuwei Cancer Hospital is the second clinical application center in China operating with independent intellectual property rights for heavy ion therapy, managed by Gansu Wuwei Cancer Hospital. Together with the first Chinese heavy ion treatment system, the second Chinese heavy ion tumor treatment system was put into clinical operation at the Lanzhou Heavy Ion Center on November 15, 2024. To date, the center has completed heavy ion and photon treatments for over 400 patients, covering conditions such as lung cancer, pancreatic cancer, liver cancer, and glioma.

To further contribute to the high-quality development of heavy ion therapy in China, building on previous work, the center is deepening clinical application research and fully advancing the iterative upgrade of heavy ion treatment technology. The "Phase II Clinical Trial Study on Carbon Ion Combined with Photon Radiotherapy for High-Grade Glioma" is now being launched. This initiative aims to align with international standards, establish clinical treatment protocols for high-grade glioma using the Chinese heavy ion system, and pursue better patient outcomes.

Recruitment Announcement

Phase II Clinical Study on Carbon Ion Combined with Photon Radiotherapy for High-Grade Glioma

Study Objectives

The Lanzhou Heavy Ion Center of Gansu Wuwei Cancer Hospital, in collaboration with the Wuwei Heavy Ion Center, is conducting a Phase II Clinical Study on Carbon Ion Combined with Photon Radiotherapy for High-Grade Glioma. This study aims to leverage the physical dosimetric and biological advantages of carbon ions to improve tumor control rates and long-term survival outcomes in patients with high-grade glioma, reduce radiation-induced damage to brain tissues associated with higher prescription doses, provide new therapeutic recommendations for glioma radiotherapy, and ultimately benefit patients.

Inclusion criteria

1. Age ≥ 14 years and ≤ 80 years;  

2. Indications: According to the fifth edition of the WHO Classification of Tumours of the Central Nervous System (2021), integrating histological features and molecular phenotypes, eligible cases include IDH-wildtype gliomas and IDH-mutant WHO grade Ⅲ/Ⅳ gliomas. All surgical extents are acceptable, including gross total resection, subtotal resection, partial resection, as well as stereotactic or open biopsy.  

3. No distant or spinal dissemination/metastasis;  

4. Pre-radiotherapy treatment status as follows: No interventional, photodynamic, or other tumor ablation therapy within 4 weeks prior to the first course of radiotherapy; surgical wound(s) must be fully healed.  

5. Good general condition, without organ function limitations, and able to tolerate the treatment;  

6. Voluntarily participate in the study and able to cooperate with treatment and follow-up.  

The above criteria serve as primary eligibility standards. Final enrollment decisions will be made by the investigator based on the trial protocol.

Patient Rights

1. The hospital will provide research funding to the expert team to cover the costs of heavy ion therapy for the patient.  

2. The glioma clinical trial project team (MDT) will develop a personalized treatment plan.  

3. After treatment, we will conduct close follow-up and provide you with subsequent treatment recommendations.

Contact Information

Contact:

Lanzhou Heavy Ion Center, Gansu Wuwei Cancer Hospital

Li Xiaojun: +86 13150160200

Zhang Yingdong: +86 18611197317